Advertisement

Tivantinib, a new option for second-line treatment of advanced hepatocellular carcinoma? The experience of Italian centers

Abstract

In the last decades the management of hepatocellular carcinoma (HCC) has undergone significant changes following the introduction of novel therapies such as sorafenib, which have improved patient survival. Nevertheless, HCC is still the third most common cause of cancer-related death worldwide. The evidence-based therapy for advanced HCC that is unsuitable for locoregional treatment is limited to sorafenib, with no second-line option available. This article focuses on the development of the MET inhibitor tivantinib in HCC as a promising treatment option for patients who failed sorafenib. A randomized, placebo-controlled phase II study showed activity of tivantinib in patients with high MET expression. Based on these results, the METIV-HCC phase III study in second-line treatment for MET-high patients was initiated to demonstrate the survival advantage of tivantinib compared to placebo.

Tumori 2015; 101(2): 139 - 143

Article Type: ORIGINAL RESEARCH ARTICLE

DOI:10.5301/tj.5000217

Authors

Lorenza Rimassa, Armando Santoro, Bruno Daniele, Domenico Germano, Antonio Gasbarrini, Stefania Salvagni, Gianluca Masi, Giovanni Abbadessa, Maria Lamar, Terri Goldberg, Camillo Porta

Article History

Disclosures

Financial disclosure and conflict of interest statements:

This article is available as full text PDF.

  • If you are a Subscriber, please log in now.

  • Article price: Eur 36,00
  • You will be granted access to the article for 72 hours and you will be able to download any format (PDF or ePUB). The article will be available in your login area under "My PayPerView". You will need to register a new account (unless you already own an account with this journal), and you will be guided through our online shop. Online purchases are paid by Credit Card through PayPal.
  • If you are not a Subscriber you may:
  • Subscribe to this journal
  • Unlimited access to all our archives, 24 hour a day, every day of the week.

Authors

Affiliations

  • Medical Oncology and Hematology Unit, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano (Milan) - Italy
  • Dipartimento di Oncologia, A.O. G. Rummo, Benevento - Italy
  • Gastroenterology Department, Catholic University of Rome, Rome - Italy
  • UOC Oncologia Medica, Azienda Ospedaliero-Universitaria di Parma, Parma - Italy
  • Divisione di Oncologia Medica Universitaria, Azienda Ospedaliero Universitaria Pisana, Pisa - Italy
  • Clnical Development, Translational Medicine, ArQule, Inc, Woburn, MA - USA
  • Clinical Development, Daiichi Sankyo, Inc, Edison, NJ - USA
  • Medical Oncology, I.R.C.C.S. San Matteo University Hospital Foundation, Pavia - Italy

Article usage statistics

The blue line displays unique views in the time frame indicated.
The yellow line displays unique downloads.
Views and downloads are counted only once per session.

No supplementary material is available for this article.